See more : PT Sekar Laut Tbk (SKLT.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Astellas Pharma Inc. (ALPMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astellas Pharma Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- FE Battery Metals Corp. (FEMFD) Income Statement Analysis – Financial Results
- Applied UV, Inc. (AUVI) Income Statement Analysis – Financial Results
- Reading International, Inc. (RDIB) Income Statement Analysis – Financial Results
- Tex-Ray Industrial Co., Ltd. (1467.TW) Income Statement Analysis – Financial Results
- Occidental Petroleum Corporation (OXY) Income Statement Analysis – Financial Results
Astellas Pharma Inc. (ALPMY)
About Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,603.67B | 1,518.62B | 1,296.16B | 1,249.53B | 1,300.84B | 1,306.35B | 1,300.32B | 1,311.67B | 1,372.71B | 1,247.26B | 1,139.91B | 1,005.61B |
| Cost of Revenue | 292.49B | 326.79B | 281.29B | 269.83B | 297.90B | 327.26B | 330.09B | 356.34B | 377.98B | 333.20B | 330.63B | 324.13B |
| Gross Profit | 1,311.19B | 1,191.83B | 1,014.87B | 979.70B | 1,002.94B | 979.09B | 970.23B | 955.33B | 994.72B | 914.06B | 809.28B | 681.49B |
| Gross Profit Ratio | 81.76% | 78.48% | 78.30% | 78.41% | 77.10% | 74.95% | 74.61% | 72.83% | 72.46% | 73.29% | 71.00% | 67.77% |
| Research & Development | 294.20B | 276.13B | 246.01B | 224.49B | 224.23B | 208.68B | 220.78B | 208.13B | 225.67B | 206.60B | 191.50B | 181.96B |
| General & Administrative | 740.11B | 630.27B | 548.84B | 504.32B | 499.30B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 259.16B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.50B |
| SG&A | 740.11B | 630.27B | 548.84B | 504.32B | 499.30B | 490.26B | 478.21B | 470.78B | 498.48B | 452.52B | 397.02B | 345.66B |
| Other Expenses | 251.36B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1,285.67B | 906.40B | 794.85B | 728.81B | 723.52B | 698.95B | 698.99B | 678.91B | 724.15B | 726.32B | 688.90B | 558.62B |
| Cost & Expenses | 1,578.15B | 1,233.19B | 1,076.14B | 998.63B | 1,021.42B | 1,026.21B | 1,029.08B | 1,035.25B | 1,102.13B | 1,059.52B | 1,019.53B | 882.75B |
| Interest Income | 11.46B | 5.21B | 794.00M | 683.00M | 2.16B | 2.69B | 1.65B | 978.00M | 985.00M | 1.94B | 1.59B | 1.81B |
| Interest Expense | 12.01B | 3.62B | 4.95B | 2.34B | 3.00B | 1.30B | 1.31B | 1.33B | 1.26B | 3.08B | 1.66B | 1.82B |
| Depreciation & Amortization | 157.84B | 105.74B | 79.68B | 72.65B | 66.40B | 63.46B | 64.86B | 63.79B | 69.19B | 65.47B | 64.30B | 57.86B |
| EBITDA | 194.81B | 246.88B | 241.52B | 220.31B | 314.75B | 313.73B | 284.76B | 347.54B | 332.59B | 258.24B | 187.94B | 180.10B |
| EBITDA Ratio | 12.15% | 25.76% | 23.12% | 25.89% | 26.58% | 26.30% | 25.85% | 25.94% | 24.75% | 23.44% | 21.70% | 21.05% |
| Operating Income | 25.52B | 285.43B | 220.02B | 250.90B | 279.42B | 280.14B | 271.24B | 276.42B | 270.58B | 226.87B | 183.09B | 153.87B |
| Operating Income Ratio | 1.59% | 18.80% | 16.97% | 20.08% | 21.48% | 21.44% | 20.86% | 21.07% | 19.71% | 18.19% | 16.06% | 15.30% |
| Total Other Income/Expenses | -549.00M | -668.00M | 711.00M | 8.80B | 3.02B | 5.06B | 4.86B | 5.35B | -8.81B | -37.19B | 5.17B | 3.08B |
| Income Before Tax | 24.97B | 131.10B | 156.40B | 144.85B | 247.01B | 248.97B | 218.11B | 281.77B | 261.77B | 189.68B | 121.97B | 124.67B |
| Income Before Tax Ratio | 1.56% | 8.63% | 12.07% | 11.59% | 18.99% | 19.06% | 16.77% | 21.48% | 19.07% | 15.21% | 10.70% | 12.40% |
| Income Tax Expense | 7.92B | 33.65B | 32.80B | 24.73B | 49.94B | 26.70B | 53.43B | 63.07B | 68.08B | 53.83B | 31.10B | 41.82B |
| Net Income | 17.05B | 98.71B | 124.09B | 120.59B | 195.41B | 222.27B | 164.68B | 218.70B | 193.69B | 135.86B | 90.87B | 82.85B |
| Net Income Ratio | 1.06% | 6.50% | 9.57% | 9.65% | 15.02% | 17.01% | 12.66% | 16.67% | 14.11% | 10.89% | 7.97% | 8.24% |
| EPS | 9.47 | 54.24 | 67.08 | 64.93 | 104.15 | 115.05 | 81.11 | 103.69 | 89.75 | 61.40 | 40.39 | 36.03 |
| EPS Diluted | 9.47 | 54.09 | 67.05 | 64.90 | 104.08 | 114.94 | 81.02 | 103.55 | 89.62 | 61.40 | 40.39 | 36.03 |
| Weighted Avg Shares Out | 1.80B | 1.82B | 1.85B | 1.86B | 1.88B | 1.93B | 2.03B | 2.11B | 2.16B | 2.21B | 2.25B | 2.30B |
| Weighted Avg Shares Out (Dil) | 1.80B | 1.83B | 1.85B | 1.86B | 1.88B | 1.93B | 2.03B | 2.11B | 2.16B | 2.21B | 2.25B | 2.30B |
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Source: https://incomestatements.info
Category: Stock Reports